A strategy for improving FDG accumulation for early detection of metastasis from primary pancreatic cancer: Stimulation of the Warburg effect in AsPC-1 cells. by 小倉 正人 & Ogura Masato
Nuclear Medicine and Biology 42 (2015) 475–481
Contents lists available at ScienceDirect
Nuclear Medicine and Biology
j ourna l homepage: www.e lsev ie r .com/ locate /nucmedb ioA strategy for improving FDG accumulation for early detection of
metastasis from primary pancreatic cancer: Stimulation of the Warburg
effect in AsPC-1 cellsMasato Ogura a,b, Naoto Shikano b,⁎, Syuichi Nakajima b, Junichi Sagara c, Naoto Yamaguchi c,
Kentaro Kusanagi b, Yuya Okui a, Asuka Mizutani a, Masato Kobayashi a,d, Keiichi Kawai a,d
a Division of Health Science, Graduate School of Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, Ishikawa 920-0942, Japan
b Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, 4669-2 Ami, Ami-machi, Inashiki-gun, Ibaraki 300-0394, Japan
c Center for Medical Sciences, Ibaraki Prefectural University of Health Sciences, 4669-2 Ami, Ami-machi, Inashiki-gun, Ibaraki 300-0394, Japan
d Biomedical Imaging Research Center, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
a b s t r a c ta r t i c l e i n f o⁎ Corresponding author. Tel.: +81 29 888 4000x6574.
E-mail address: sikano@ipu.ac.jp (N. Shikano).
http://dx.doi.org/10.1016/j.nucmedbio.2014.12.017
0969-8051/© 2015 Elsevier Inc. All rights reserved.Article history:
Received 12 December 2014
Received in revised form 25 December 2014







Introduction: Early detection and/or prediction of metastasis providemore prognostic relevance than local recur-
rence. Direct spread into the peritoneum is frequently found in pancreatic cancer patients, but positron emission
tomography (PET) with 2-deoxy-2-ﬂuoro-D-glucose (FDG) is not useful for identifying such metastasis. We in-
vestigated a method to enhance FDG accumulation using AsPC-1 human ascites tumor cells.
Methods: 14C-FDG accumulation was assessed under the following conditions: 1) characteristics of 14C-FDG
transport were examined using phloridzin, a Na+-free buffer, and various hexoses, and 2) accumulation of
14C-FDG was measured in cells that were pretreated with hexose for various time periods, and activity of
6-phosphofructo-1-kinase (PFK-1) was assayed.
Results: 14C-FDG transport into AsPC-1 cells was mediated primarily by a Na+-independent transport mecha-
nism. Aldohexoses such as D-glucose, D-mannose, and D-galactose inhibited 14C-FDG transport. Cells pretreated
with D-glucose, D-mannose, or D-fructose exhibited augmented 14C-FDG accumulation. Pretreatmentwith higher
concentrations of D-glucose or D-fructose tended to increase PFK-1 activity.
Conclusions: Very little information has been published about the association between PFK-1 and FDG accumula-
tion, and we conﬁrmed the impacts of various hexoses on the activity of PFK-1 and FDG accumulation in AsPC-1
cells. Clarifying the relevance of PFK-1 in FDG accumulation will contribute to developing new features of FDG-
PET, because PFK-1 is the main regulator of glycolysis.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Pancreatic cancer (PC) is highly aggressive, and its mortality rates
have been approximately stable in many European countries, the USA,
Japan, and Australia over the last few years [1]. Retrospective analysis
has demonstrated that a dramatic change in surgical resectability and
patient survival occurs as the size of the PC tumor increases from
20 mm to 30 mm [2,3]. Moreover, PC patient survival is dependent on
distant metastasis rather than local recurrence, and therefore, early de-
tection and/or prediction of metastasis provide more prognostic rele-
vance than local recurrence [4].
Direct spread into the peritoneum is not uncommon in PC patients,
but positron emission tomography (PET) with 2-deoxy-2-ﬂuoro-D-
glucose (FDG) is not useful for identifying such metastasis, especially
microscopic peritoneal dissemination (b10 mm) and intraperitoneal
seeding, because of the low concentration of cancer cells [5–7].In acute hyperglycemia, FDG transport may decrease because of
competition between FDG and D-glucose [8]. Numerous reports exam-
ining the relationship between FDG accumulation and D-glucose have
been published [9–13]. In contrast, whether other hexoses are involved
in FDG accumulation has yet to be determined, either in vivo or in vitro.
A future objective of ours is to be able to assess peritonealmetastasis
with FDG-PET. Thus, in the present study, we investigated a method to
enhance FDG accumulation using AsPC-1 human ascites tumor cells
from a PC patient.
2. Materials and methods
2.1. Materials
Reagent grade D-glucose, L-glucose, and D-allose were purchased
fromWako Pure Chemical Industries, Ltd. (Osaka, Japan), and D-altrose,
D-gulose, D-sorbose, and D-tagatose were purchased from Kanto Chemical
Co., Inc. (Tokyo, Japan). D-mannose, D-galactose, D-fructose, L-fructose,
D-fructose 6-phosphate (D-Fru-6-P), aldolase, α-glycerophosphate
476 M. Ogura et al. / Nuclear Medicine and Biology 42 (2015) 475–481dehydrogenase-triosephosphate isomerase, and the other chemicals
were purchased fromSigma-Aldrich Japan (Tokyo, Japan). The radiolabeled
compounds 14C-FDG, 14C-maltose, and 14C-inulin were purchased from
American Radiolabeled Chemicals Co. (St. Louis, MO, USA).
2.2. Cell culture
AsPC-1 human ascites tumor cells were obtained from the American
Type Culture Collection (Rockville, MD, USA). Cells were incubated in
Dulbecco’s Modiﬁed Eagle’s Medium (Sigma-Aldrich Japan) supple-
mented with L-glutamine (2 mM ﬁnal concentration) and fetal bovine
serum (10% ﬁnal concentration; Nichirei Biosciences Inc., Tokyo,
Japan) at 37 °C in a 10% CO2 atmosphere. Cells were maintained in
25-cm2 cell culture ﬂasks (Nalge Nunc International, Roskilde,
Denmark) and were passaged every 4 days using 0.1% trypsin and
0.04% EDTA. AsPC-1 cells (5×105 cells per dish)were seeded in a plastic
culture dish (60-mm diameter; Nalge Nunc International) and were
used in the experiments described below 4 days after seeding. At the
time experiments were initiated, the cell density was approximately
2.5 × 106 cells/dish. Before experiments, the culture medium was re-
moved from the dish, and the cells were rinsed once with Dulbecco’s
phosphate-buffered saline (D-PBS; Sigma-Aldrich Japan).
2.3. Characteristics of 14C-FDG transport into AsPC-1 cells
14C-FDG accumulation experiments were performed according to
previously reported methods, with modiﬁcations [14,15]. For time-
course experiments, AsPC-1 cellswere rinsedwithD-PBS and then incu-
bated with 2 ml D-PBS containing 14C-FDG (14C-FDG D-PBS; 9.25 kBq/
dish) at 37 °C for a speciﬁc period (15 to 180 min). The 14C-FDG D-
PBS was then removed by aspiration, and the cells were immediately
rinsed twice with 5 ml ice-cold D-PBS. Next, the cells were lysed over-
night in 2 ml 0.2 M NaOH, and the radioactivity in the NaOH extract
was assayed using a Tri-carb 2910TR liquid scintillation analyzer
(PerkinElmer Japan Co., Ltd., Kanagawa, Japan). Similar experiments
using radiolabeled 14C-maltose D-PBS (9.25 kBq/dish) or 14C-inuline
D-PBS (9.25 kBq/dish) were performed as described above.
To examine the characteristics of 14C-FDG transport into AsPC-1
cells, we carried out experiments using 14C-FDG D-PBS in 1 mM
phloridzin or Na+-free buffer. Phloridzin is a speciﬁc inhibitor of the
Na+-dependent glucose transporter family [16]. In experiments with
the Na+-free buffer, NaCl and Na2HPO4 in the D-PBS were replaced
with the same concentrations of choline chloride and K2HPO4,
respectively. Cells were incubated in phloridzin-containing buffer or
Na+-free buffer for 60 min, and then the radioactivity present in the
cell extract was measured as described above. To suppress 14C-FDG
entry via transporters, cells were kept on ice during all incubations.
2.4. Competitive inhibition of 14C-FDG transport
To conﬁrm the competitive effects of hexoses on 14C-FDG trans-
port into AsPC-1 cells, the following modiﬁcations were incorporat-
ed into competitive inhibition experiments: 1) 14C-FDG D-PBS
contained one of the following 11 hexoses (D-/L-glucose, D-mannose,
D-allose, D-galactose, D-altrose, D-gulose, D-/L-fructose, D-sorbose, or
D-tagatose) at a concentration of 1 mM, and 2) 14C-FDG D-PBS
contained an indicated concentration (0.01 to 100 mM) of one select
hexose (D-/L-glucose, D-mannose, D-galactose, or D-fructose). After
incubation in 14C-FDG D-PBS for 60 min, the radioactivity present
in the cell extract was measured as described above.
2.5. 14C-FDG accumulation in pretreated AsCP-1 cells
To examine the effect of pretreating AsPC-1 cells with hexoses on
14C-FDG accumulation, the following modiﬁcations were incorporated
into the pretreatment experiments: 1) D-PBS contained one of thefollowing 11 hexoses (D-/L-glucose, D-mannose, D-allose, D-galactose,
D-altrose, D-gulose, D-/L-fructose, D-sorbose, or D-tagatose) at a
concentration of 1mM, and 2) D-PBS contained an indicated concentra-
tion (0.01 to 100 mM) of one select hexose (D-/L-glucose, D-mannose,
D-galactose, or D-fructose). Cells were incubated in one of the above
D-PBS solutions for 60 min, and then immediately rinsed twice with
D-PBS and incubated with 14C-FDG D-PBS for 60 min. Following cell
lysis, the radioactivity present in the cell extract was measured as de-
scribed above. A pretreatment time of 60minwas chosen because incu-
bations less than 60 min produced no augmentation of FDG
accumulation in our preliminary experiments.
2.6. 6-Phosphofructo-1-kinase activity in pretreated AsPC-1 cells
For the time-course experiments, AsPC-1 cells were exposed to 1 or
100 mM D-glucose or D-fructose for a speciﬁc period (15 to 60 min),
after which the cells were immediately rinsed twicewith D-PBS and re-
moved from the culture dish with a rubber policeman.
To measure the 6-phosphofructo-1-kinase (PFK-1) activity in cells
pretreated with various hexoses, cells were incubated at 37 °C for
60 min in D-PBS containing D-/L-glucose, D-mannose, D-galactose, or
D-/L-fructose at concentrations ranging from 1 to 100 mM, and then re-
moved from the culture dish with a rubber policeman.
The collected cells were homogenized on ice in extraction buffer
comprised of 50mMTris-phosphate (pH 8.0), 0.2 mMethylenediamine
tetraacetic acid (EDTA), 90 mM potassium ﬂuoride, 10 mM dithiothrei-
tol (DTT), and 1 mM phenylmethylsulfonyl ﬂuoride [17]. The homoge-
nates were centrifuged at 29,000 × g for 30 min at 4 °C using a himac
CS100FX ultracentrifuge (Hitachi Koki Co. Ltd., Tokyo, Japan).
PFK-1 activity in the supernatants was measured as previously de-
scribed [14]. The reaction mixture contained 50 mM Tris–HCl
(pH 8.0), 1 mM EDTA, 2 mM MgCl2, 2 mM DTT, 5 mM (NH4)2SO4,
1 mM D-Fru-6-P, 1.2 mM adenosine 5′-triphosphate, 0.2 mM
reduced nicotinamide adenine dinucleotide (NADH), 0.8 U/ml aldolase,
0.8 U/ml α-glycerophosphate dehydrogenase, and 8.7 U/ml
triosephosphate isomerase in a ﬁnal volume of 1 ml. The reaction was
initiated by addition of the extract (30 μl), and the absorbance at
340 nm was measured at 37 °C using a UV-2200 spectrophotometer
(Shimadzu Corp., Kyoto, Japan). PFK-1 activity was calculated as fol-
lows: 1 mol D-fructose 1,6-bisphosphate (D-Fru-1,6-P2) = 2 mol
NADH consumed. The NADH content in the homogenates was calculat-
ed using the absorption coefﬁcient of NADH (6220 M−1•cm−1) [18].
2.7. Statistical analysis
Values obtained in each experiment are presented as the mean ±
SD. Groups were compared using ANOVA followed by Dunnett’s post-
hoc analysis. Differences were considered statistically signiﬁcant at
P b 0.05.
3. Results
3.1. Characterization of 14C-FDG accumulation in non-pretreated
AsPC-1 cells
14C-FDG transport into AsPC-1 cells was time dependent during the
initial 60 min, and was saturated at approximately 35% of the adminis-
tered dose by 120 min (Fig. 1a). No 14C-inulin was detected in the cells,
indicating that no error was present in the methodology that
would have resulted in accumulation of radioactivity not associated
with 14C-FDG. In addition, radiolabeled 14C-maltose did not accumulate
in cells.Maltosemust be enzymaticallymetabolized (e.g., maltase in the
small intestine) before entry into cells.
The accumulation of 14C-FDG after 60min in various conditions is
shown in Fig. 1b. Low temperature suppressed total 14C-FDG accu-
mulation to 35% of the control, suggesting that FDG transport is
Fig. 1.Characteristics of 14C-FDG accumulation inAsPC-1 cells. (a) Time course of 14C-FDG (♦), 14C-maltose (▲), and 14C-inulin (○) accumulation. Accumulation (% of administereddose) is
plotted against time after administration. (b) 14C-FDG transport in AsPC-1 cells under various conditions. Black columns and white columns represent 14C-FDG accumulation in cells in-
cubated in D-PBS and in Na+-free buffer, respectively. Values represent the mean ± SD. n = 4–8. *P b 0.05; n.s., not signiﬁcant.
477M. Ogura et al. / Nuclear Medicine and Biology 42 (2015) 475–481carrier mediated. Transport of 14C-FDG via Na+-independent and
Na+-dependent mechanisms was approximately 40% and 25%, re-
spectively. In the presence of phloridzin, a Na+-dependent glucose
transporter inhibitor, 14C-FDG accumulation was reduced by ap-
proximately 25% relative to the control. 14C-FDG transport into
AsPC-1 cells is thus mediated primarily by a Na+-independent trans-
port mechanism.Fig. 2. Competitive inhibition of 14C-FDG transport by various hexoses. The effect of 1 mM aldoh
(c) Effect of 0.01 to 100 mM D-glucose (♦), D-mannose (●), D-galactose (▲), D-fructose (■), or
corresponding control.3.2. Competitive inhibition of 14C-FDG transport
The results of competitive inhibition experiments of 14C-FDG trans-
port by D-/L-hexoses (1mM) are shown in Fig. 2a. Three aldohexoses in-
cluding D-glucose, D-mannose, and D-galactose inhibited 14C-FDG
accumulation. As L-glucose is not transported via glucose transporter
proteins and does not inhibit 2-deoxyglucose transport [19,20],exose (a) or ketohexose (b). 14C-FDG accumulation was normalized to that of the control.
L-glucose (×) in 14C-FDG D-PBS. Values represent the mean ± SD. n = 4–8. *P b 0.05 vs.
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of the D-/L-ketohexoses we examined had any signiﬁcant inhibitory
effect (Fig. 2b). As shown in Fig. 2c, D-glucose and D-mannose
strongly inhibited 14C-FDG transport at all concentrations tested, and
D-galactose had an inhibitory effect at concentrations above 1 mM.
Lower concentrations (0.01 and 0.1 mM) of D-fructose augmented
14C-FDG accumulation (121.4 ± 1.1% and 117.1 ± 0.5% of control,
respectively), and 100 mM D-fructose had an inhibitory effect (45.7 ±
1.4% of control).
3.3. 14C-FDG accumulation in AsPC-1 cells pretreated with hexoses
As shown in Fig. 3a and b, 14C-FDG accumulation was augmented in
AsPC-1 cells pretreated with 1 mM D-glucose, D-mannose, or D-fructose
(147.8±18.6%, 129.0±4.3%, or 125.0±15.6% of control, respectively).
In contrast, pretreating cells with 1mM D-galactose, D-altrose, D-gulose,
or L-glucose had no signiﬁcant effect on 14C-FDG accumulation. Pre-
treatment with D-allose resulted in a slight decrease in 14C-FDG accu-
mulation. Ketohexoses other than D-fructose (D-sorbose, D-tagatose,
and L-fructose) did not have any effect on 14C-FDG accumulation.
The effect of pretreating cells with D-glucose, D-mannose, D-galactose,
or D-fructose at concentrations ranging from 0.01 to 100 mM is shown
in Fig. 3c. We chose to also include D-galactose because Miller demon-
strated that D-galactose increased the velocity of hexose transport
[21]. Signiﬁcant effects were observed in cells pretreatedwith D-glucose
(0.01 to 100 mM), D-mannose (1 to 100 mM), D-galactose (10 andFig. 3. 14C-FDG accumulation in AsPC-1 cells pretreatedwith one hexose. Pretreatment with 1m
control (black columns). *P b 0.05 vs. corresponding control. (c) Pretreatmentwith 0.01 to 100m
represent the mean ± SD. n = 4–8. Signiﬁcant effects were observed with all of the hexoses w100 mM), and D-fructose (1 to 100 mM). Pretreating cells with
100 mM D-mannose led to a decrease in 14C-FDG accumulation. Pre-
treatment with L-glucose had no effect on 14C-FDG accumulation at
any concentration tested.
3.4. PFK-1 activity in AsPC-1 cells pretreated with hexoses
Longer pretreatments resulted in greater enhancement of PFK-1
activity in control cells or in cells pretreated with D-glucose (1 mM) or
D-fructose (1, 100 mM) (Table 1). An increase in PFK-1 activity relative
to the control in cells pretreated with 100 mM D-glucose or D-fructose
was observed at all time points examined.
To examine the effect of pretreatment with various concentrations
of hexoses, we chose D-glucose, D-mannose, D-galactose, and D-fructose,
which augmented 14C-FDG accumulation. As shown in Fig. 4a and b,
pretreatment with higher concentrations of D-glucose or D-fructose
tended to increase PFK-1 activity. We found no difference in PFK-1
activity relative to the control in cells pretreated with L-glucose
(1 mM), L-fructose (1 mM), D-mannose (1 to 100 mM), or D-galactose
(1 to 100 mM).
4. Discussion
In this study, 14C-FDG accumulation was augmented signiﬁcantly
compared to controls in AsPC-1 cells pretreated with 1 mM D-glucose,
D-mannose, or D-fructose for 60 min. We previously reported that L-M(a) aldohexose or (b) ketohexose. 14C-FDG accumulationwas normalized to that of the
MD-glucose (♦), D-mannose (●), D-galactose (▲), D-fructose (■), or L-glucose (×). Values
e examined.
Table 1













Control 0 15 20.88 ± 0.16 –
D-glucose 1 15 22.78 ± 0.34 109 ⁎
100 15 24.39 ± 0.20 117 ⁎
D-fructose 1 15 23.71 ± 0.34 114 ⁎
100 15 23.85 ± 0.48 114 ⁎
Control 0 30 24.90 ± 0.87 –
D-glucose 1 30 26.21 ± 0.17 105
100 30 27.63 ± 0.51 111 ⁎
D-fructose 1 30 25.86 ± 0.40 104
100 30 27.70 ± 0.04 111 ⁎
Control 0 60 25.66 ± 3.92
D-glucose 1 60 23.99 ± 0.35 94 ⁎
100 60 32.02 ± 0.16 125 ⁎
D-fructose 1 60 28.32 ± 0.27 110
100 60 37.11 ± 0.94 145 ⁎
The activity of PFK-1 was expressed as the amount of NADH consumed (nmol/min/mg
protein). Values represent the mean ± SD. n = 3–6.
⁎ P b 0.05 vs. corresponding control.
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analog, which prompted us to examine effects on FDG accumulation
in cells pretreated with hexoses [15]. Similar induction of sugar trans-
port was reported by Miller, who observed accelerated sugar out-ﬂow
[21]. Such an acceleration of substrate transport is an obligatory
exchange mechanism in amino acid transport [15,22]. Our preliminary
experiments, however, did not show acceleration of the out-ﬂow of
14C-FDG when hexose was present outside the cell, and we hypothe-
sized that augmentation of FDG accumulation is due to elevation in
the levels of intracellular glycolytic enzymes, not acceleration in the
obligatory exchange.
Control of glycolysis is usually explained in terms of the allosteric
properties of three enzymes: hexokinase, PFK-1, and pyruvate kinase.
Many (or all) of the glycolytic enzymes in cancer cells have been sug-
gested to be overexpressed [23,24]. Although numerous studies investi-
gating the association between FDG accumulation and glucose
transporters or hexokinase have been published, the effects of the
main regulator of glycolysis, PFK-1, on FDG accumulation have not
been thoroughly explored [25–28].Fig. 4. PFK-1 activity in homogenates of AsPC-1 cells pretreated with one hexose. Pretreatme
aldohexose (a) or ketohexose (b). PFK-1 activities were normalized to the activity of th
corresponding control.We focused our investigation on PFK-1, because its phosphorylation
step is considered the major rate-limiting reaction and surmounts the
regulatory roles of hexokinase and pyruvate kinase [29]. Consistent
with the results obtained from Malaisse et al. [30] and Colomer et al.
[31], our results demonstrated elevation of PFK-1 activity in AsPC-1
cells pretreated with D-glucose or D-fructose. The roles of these hexoses
in the metabolism of cancer cells have been thoroughly investigated. In
the early 20th century, D-fructosewas shown to be converted into lactic
acid more rapidly than D-glucose, and cancer cells were shown to rely
on aerobic glycolysis, a phenomenon known as “the Warburg effect”
[32,33]. PFK-1 mediates the phosphorylation of D-Fru-6-P to D-Fru-
1,6-P2 using ATP, and is regulated allosterically by the level of D-fructose
2,6-bisphosphate (D-Fru-2,6-P2) [34]. The level of the allosteric
regulator D-Fru-2,6-P2 is controlled by a bifunctional enzyme,
6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase (PFK-2/
FBPase). PFK-1 and PFK-2/FBPase share the same substrate, and PFK-
2/FBPase is capable of phosphorylating D-Fru-6-P to D-Fru-2,6-P2 or de-
phosphorylating D-Fru-2,6-P2 to D-Fru-6-P [35].
Human PFK-1 is expressed as three isozymes, type-M, -L, and -P,
which undergo random tetramerization to produce various homo-
and heterotetrameric isozymes, each of which shows different kinetic
properties [36]. Active investigations continue to elucidate alterations
in gene expression and enzymatic activity of these isozymes regarding
high energy production in cancer [29,35,37]. Colomer et al. have report-
ed that PFK-1 from cancer cell extracts is more sensitive to an activation
effect by D-Fru-2,6-P2 than normal cells, although the intracellular levels
of D-Fru-2,6-P2 are equal in both normal and cancer cells [31]. Sanchez-
Martinez et al. demonstrated that ascites tumor cells mainly express
PFK-1 type-P, whereas type-L is the more abundant isozyme in normal
mammary glands [38]. Wang et al. recently reported that enhancement
of glycolytic activity depends on the conversion of PFK-1 isozyme from
type-L to type-P during the development of cancer [39]. Consequently,
PFK-1 type-P may contribute to maintaining a high glycolytic status in
cancer cells [40]. Another report, however, showed that PFK-1 activity
is negligible for glycolytic ﬂux control in hepatoma cells [41]. The char-
acteristics of PFK-1 should be further clariﬁed in future studies.
Because of the inhibitory effects of PFK-2/FBPase, which regulates
the D-Fru-2,6-P2 level and leads to a reduction in PFK-1 activity, anti-
metabolic agents have been investigated [29,42,43]. Expression of the
PFK-2/FBPase gene is markedly elevated in cancer cells, resulting in
stimulation of glycolysis [44]. Clem et al. concluded that their novel
class of antimetabolic agents selectively suppresses glucose uptake bynt with 1 mM (white columns), 10 mM (hatched columns), or 100 mM (gray columns)
e control (black columns). Values represent the mean ± SD. n = 3–6. *P b 0.05 vs.
480 M. Ogura et al. / Nuclear Medicine and Biology 42 (2015) 475–481cancer in vivo and that glucose uptake measurements by FDG scans can
be used as pharmacodynamic endpoints in clinical trials [42].We expect
that FDG-PETwill play a role as a predictivemodality for the therapeutic
effects of PFK-1 inhibitors.
Because the only curative treatment for PC patients is surgical resec-
tion, detection and/or assessment of dissemination or seeding in the
peritoneum by FDG-PET are important for selecting patients who will
beneﬁt from PC resection and for avoiding unnecessary surgery
(surgical resection beneﬁts only patients with localized disease) [45].
In this study, we demonstrated that pretreating cells with hexoses aug-
ments FDG accumulation, and D-fructosewas themost effective at stim-
ulating an increase in FDG accumulation among the hexoses we
examined. Nutrient treatment before injection of metabolic imaging
agents may effectively enhance tracer accumulation by cancer cells
[22]. Oral administration of D-fructose leads to transient elevation of
the level of D-fructose in the blood [46].
Very little has been published in the literature about the association
between PFK-1 and FDG accumulation, andwe conﬁrmed the impact of
various hexoses on the activity of PFK-1 and FDG accumulation in AsPC-
1 cells. Although PFK-1 in cancer cells has been thoroughly investigated,
further studies are needed to clarify the PFK-1 characteristics that are
relevant to FDG accumulation. Such investigationswill identify new fea-
tures of FDG-PET; e.g., the detection of microscopic ascites tumor cells
and prediction of the effect of novel metabolic agents. In future work,
we will use in vivo studies to investigate how each treatment with
each hexose impacts FDG accumulation in various cancer cells.
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